Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Glofitamab, venetoclax, and lenalidomide combination shows promising efficacy in high-risk mantle cell lymphoma

Dr Tycel Phillips - City of Hope National Medical Center, Duarte, USA
Glofitamab, venetoclax, and lenalidomide combination shows promising efficacy in high-risk mantle cell lymphoma ( Dr Tycel Phillips - City of Hope National Medical Center, Duarte, USA )
18 Dec 2025

Ropeginterferon alfa-2b is evaluated as a disease-modifying option in essential thrombocythemia

Prof Jean-Jacques Kiladjian - Hôpital Saint-Louis, Paris, France
Ropeginterferon alfa-2b is evaluated as a disease-modifying option in essential thrombocythemia ( Prof Jean-Jacques Kiladjian - Hôpital Saint-Louis, Paris, France )
18 Dec 2025

Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL

Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany
Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL ( Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany )
17 Dec 2025

IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis

Dr Keith McCrae - Cleveland Clinic, Cleveland, USA
IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis ( Dr Keith McCrae - Cleveland Clinic, Cleveland, USA )
17 Dec 2025

AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer

Dr Roberto Salgado - Peter MacCallum Cancer Centre, Melbourne, Australia
AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer ( Dr Roberto Salgado - Peter MacCallum Cancer Centre, Melbourne, Australia )
16 Dec 2025

AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab

Dr Roberto Salgado - Peter MacCallum Cancer Centre, Melbourne, Australia
AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab ( Dr Roberto Salgado - Peter MacCallum Cancer Centre, Melbourne, Australia )
16 Dec 2025

New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types

Dr Xiaoming Zhong - St. Jude Children's Research Hospital, Memphis, USA
New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types ( Dr Xiaoming Zhong - St. Jude Children's Research Hospital, Memphis, USA )
10 Dec 2025

Tec-Dara significantly improves PFS and OS compared to SoC in relapsed/refractory multiple myeloma

Dr Luciano Costa - University Of Alabama At Birmingham, Birmingham, USA
Tec-Dara significantly improves PFS and OS compared to SoC in relapsed/refractory multiple myeloma ( Dr Luciano Costa - University Of Alabama At Birmingham, Birmingham, USA )
10 Dec 2025

Black patients show inferior survival despite similar cytogenetics and treatment response

Prof Shella Saint Fleur-Lominy - University of Maryland School of Medicine, Baltimore, USA
Black patients show inferior survival despite similar cytogenetics and treatment response ( Prof Shella Saint Fleur-Lominy - University of Maryland School of Medicine, Baltimore, USA )
10 Dec 2025

Asciminib shows high molecular response, favourable safety in 2L CML-CP

Dr Jorge Cortes - Georgia Cancer Center, Augusta, USA
Asciminib shows high molecular response, favourable safety in 2L CML-CP ( Dr Jorge Cortes - Georgia Cancer Center, Augusta, USA )
10 Dec 2025

Rocbrutinib shows strong responses in resistant CLL, including BTKi- and venetoclax-exposed patients

Prof Jennifer Woyach - The Ohio State University, Columbus, USA
Rocbrutinib shows strong responses in resistant CLL, including BTKi- and venetoclax-exposed patients ( Prof Jennifer Woyach - The Ohio State University, Columbus, USA )
10 Dec 2025

First-line use of tepotinib in METex14 NSCLC: A patient-centered journey

Dr Ryan Nguyen, Rebecca Timogtimog, Carmela Timogtimog
First-line use of tepotinib in METex14 NSCLC: A patient-centered journey ( Dr Ryan Nguyen, Rebecca Timogtimog, Carmela Timogtimog )
10 Dec 2025